83
Participants
Start Date
December 12, 2018
Primary Completion Date
June 22, 2022
Study Completion Date
June 22, 2022
HB-101 vaccine
HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.
placebo
Saline will be used for placebo.
Odense University Hospital, Odense
Charite Universitatsmedizin Berlin, Berlin
Thomas E. Starzl Transplantation Institute, Pittsburgh
CHU de Toulouse - Hospital Rangueil, Toulouse
Centre Hospitalier Universitaire de Bordeaux Hôpital Pellegrin, Bordeaux
The 1917 Clinic at UAB, Birmingham
University Hospitals Cleveland Medical Center, Cleveland
Universitatsklinikum Essen, Essen
The Christ Hospital, Cincinnati
University of Cincinnati (UC) - College of Medicine, Cincinnati
Indiana University/IU Health, Indianapolis
Oklahoma University, Oklahoma City
South Texas Accelerated Research, Dallas
Hopital Necker-Enfants Malades, Paris
University of Colorado Hospital, Aurora
California Institute of Renal Research, La Mesa
UC Davis Health Systems, Sacramento
Swedish Medical Center, Seattle
Massachusetts General Hospital, Boston
Oslo University Hospital, Oslo
Belfast Health and Social Care Trust, Belfast
Cardiff & Vale University Health Board, Cardiff
St James's University Hospital, Leeds
Leicester General Hospital, Leicester
The Royal Free Hospital, London
Lead Sponsor
Hookipa Biotech GmbH
INDUSTRY